4D pharma plc

Informe acción AIM:DDDD

Capitalización de mercado: UK£30.0m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

4D pharma Dirección

Dirección controles de criterios 3/4

Información clave

Duncan Peyton

Chief Executive Officer (CEO)

US$343.5k

Compensación total

Porcentaje del salario del CEO98.8%
Permanencia del CEO9yrs
Participación del CEO5.6%
Permanencia media de la dirección8.7yrs
Promedio de permanencia en la Junta Directiva4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Do Insiders Own Lots Of Shares In 4D pharma plc (LON:DDDD)?

Mar 09
Do Insiders Own Lots Of Shares In 4D pharma plc (LON:DDDD)?

Is 4D pharma plc (LON:DDDD) Popular Amongst Insiders?

Nov 24
Is 4D pharma plc (LON:DDDD) Popular Amongst Insiders?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Duncan Peyton en comparación con los beneficios de 4D pharma?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2021US$343kUS$339k

-US$32m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$41m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$139kUS$137k

-US$30m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$135kUS$132k

-US$30m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$130kUS$127k

-US$30m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$25m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$136kUS$136k

-US$28m

Sep 30 2017n/an/a

-US$25m

Jun 30 2017n/an/a

-US$22m

Mar 31 2017n/an/a

-US$17m

Dec 31 2016US$124kUS$124k

-US$12m

Compensación vs. Mercado: Duncan's total compensation ($USD343.49K) is about average for companies of similar size in the UK market ($USD341.99K).

Compensación vs. Ingresos: Duncan's compensation has increased whilst the company is unprofitable.

CEO

Duncan Peyton (52 yo)

9yrs

Permanencia

US$343,489

Compensación

Mr. Duncan Joseph Peyton is a Co-founder of Retroscreen Virology Group plc. Mr. Peyton serves as Chief Executive Officer at 4D pharma plc. since February 2014.Mr. Peyton served at Aquarius Equity Partners...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Duncan Peyton
CEO & Executive Director9yrsUS$343.49k5.55%
$ 1.7m
Alexander Stevenson
Chief Scientific Officer & Executive Director8.7yrsUS$294.81k5.4%
$ 1.6m
John Doyle
Chief Financial Officer1.1yrssin datossin datos
Fay Weston
Head of Investor Relationsno datasin datossin datos
Adrian Murray
General Counsel (Interim)no datasin datossin datos
Glenn Dourado
Executive Vice President of Corporate Developmentno datasin datossin datos
Lucy Christie
Vice President of Human Resourcesno datasin datossin datos
Christophe Carite
Senior Vice President of CMC & Process Developmentno datasin datossin datos
Imke Mulder
Executive Vice President of Researchno datasin datossin datos

8.7yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: DDDD's management team is seasoned and experienced (8.7 years average tenure).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Duncan Peyton
CEO & Executive Director9.1yrsUS$343.49k5.55%
$ 1.7m
Alexander Stevenson
Chief Scientific Officer & Executive Director9.1yrsUS$294.81k5.4%
$ 1.6m
Paul Maier
Independent Non-Executive Director1.9yrsUS$90.61ksin datos
Edgardo Baracchini
Independent Non-Executive Director4.1yrsUS$93.31ksin datos
Katrin Rupalla
Independent Non-Executive Director2.4yrsUS$93.31ksin datos
Alexander Macrae
Independent Non-Executive Director3.5yrsUS$100.07ksin datos
Axel Glasmacher
Independent Non-Executive Chairperson4.1yrsUS$139.29k0.017%
$ 5.0k

4.1yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: DDDD's board of directors are considered experienced (4.1 years average tenure).